Australian nuclear medicine company Radiopharm Theranostics (ASX:RAD) has strengthened its board with the appointment of highly regarded life sciences leader Bruce Goodwin as a Non-Executive Director, effective 19 November 2025.
The ASX-listed radiopharmaceutical company said the appointment marks another step in its strategy to enhance governance and deepen global industry expertise as it advances a growing clinical pipeline.
Goodwin brings more than 40 years of experience across the global healthcare and biopharmaceutical sectors, including over three decades with Janssen, the pharmaceutical arm of Johnson & Johnson. Over the course of his international career, he held senior leadership roles across multiple markets and served on the board of Medicines Australia. He built a reputation for driving organisational growth, fostering innovation, and leading high-performing teams in complex multinational environments. He currently serves on six healthcare sector boards, providing strategic guidance and governance support.
Mr Goodwin is the current chair of Rare Cancers Australia and serves on the board of the Australian Genomic Cancer Medicine Centre (Omico).
Radiopharm Executive Chairman Paul Hopper said Goodwin’s appointment adds significant depth to the board at a pivotal stage for the company. “His exceptional leadership experience, particularly his long tenure with Johnson & Johnson and deep understanding of the biopharmaceutical landscape, will be invaluable as we continue to advance our pipeline and strengthen our global profile,” Hopper said.
Radiopharm, which is dual-listed on the ASX and NASDAQ, is progressing a portfolio of radiotherapeutic and diagnostic candidates across multiple solid tumour indications, including programs currently in Phase 1 and Phase 2 clinical trials.